Management of Hypertension and Cerebrovascular Disease in the Elderly

American Journal of Medicine

Volumn 121, Issue 8 SUPPL. 1, 2008, Pages

  Pedelty, Laura ^a   Gorelick, Philip B ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Ambulator; Blood pressure monitoring; Elderly; Hypertension; Stroke prevention; Vascular cognitive impairment

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CLOPIDOGREL; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; DIURETIC AGENT; ENALAPRIL; EPROSARTAN; HYDROCHLOROTHIAZIDE; INDAPAMIDE; LOSARTAN; NITRENDIPINE; PERINDOPRIL; PLACEBO; RAMIPRIL; TELMISARTAN; THIAZIDE DIURETIC AGENT;

ADD ON THERAPY; AGING; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; BRAIN ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; DEMENTIA; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; GERIATRIC PATIENT; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; LEARNING; LOW DRUG DOSE; MEMORY; MONOTHERAPY; NEUROPROTECTION; ORTHOSTATIC HYPERTENSION; PATIENT MONITORING; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK ASSESSMENT; RISK REDUCTION; STROKE; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME;

AGE FACTORS; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CEREBROVASCULAR DISORDERS; HUMANS; HYPERTENSION; INCIDENCE; PROGNOSIS; RISK FACTORS; UNITED STATES;

EID: 47149106833     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2008.05.019     Document Type: Article

References (64)

1. World Health Organization. Global burden of stroke. In: MacKay J., and Mensah G. (Eds). The Atlas of Heart Disease and Stroke (2004). http://www.who.int/cardiovascular_diseases/resources/atlas/en/ Accessed October 27, 2007
2. Kleindorfer D., Panagos P., Pancioli A., et al. Incidence and short-term prognosis of transient ischemic attack in a population-based study. Stroke 36 (2005) 720-723
3. Tatemichi T.K., Paik M., Bagiella E., et al. Risk of dementia after stroke in a hospitalized cohort: results of a longitudinal study. Neurology 44 (1994) 1885-1891
4. Johnston S.C., Gress D.R., Browner W.S., and Sidney S. Short-term prognosis after emergency department diagnosis of TIA. JAMA 284 (2000) 2901-2906
5. Lewington S., Clarke R., Qizilbash N., Peto R., Collins R., and Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360 (2002) 1903-1913
6. van Wijk I., Kappelle L.J., van Gijn J., et al., LiLAC Study Group. Long-term survival and vascular event risk after transient ischaemic attack or minor ischaemic stroke: a cohort study. Lancet 365 (2005) 2098-2104
7. Goldstein L.B., Adams A., Alberts M.J., et al. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group, Cardiovascular Nursing Council, Clinical Cardiology Council, Nutrition, Physical Activity, and Metabolism Council, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 113 (2006) e873-e923
8. Sacco R.L., Adams A., Albers G., et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke, co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Circulation 113 (2006) e409-e449
9. Chobanian A.V., Bakris G.L., Black H.R., et al., National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and the National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42 (2003) 1206-1252
10. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 157 (1997) 2413-2446
11. Black H.R. The paradigm has shifted to systolic blood pressure. J Hum Hypertens 18 suppl 2 (2004) S3-S7
12. Kannel W.B., Dawber T.R., Sorlie P., and Wolf P.A. Components of blood pressure and risk of atherothrombotic brain infarction: the Framingham study. Stroke 7 (1976) 327-331
13. Franklin S.S., Jacobs M.J., Wong N.D., L'Italien G.J., and Lapuerta P. Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension 37 (2001) 869-874
14. Román G.C. Vascular dementia prevention: a risk factor analysis. Cerebrovasc Dis 20 suppl 2 (2005) 91-100
15. Román G.C., Erkinjuntti T., Wallin A., Pantoni L., and Chui H.C. Subcortical ischaemic vascular dementia. Lancet Neurol 1 (2002) 426-436
16. Vermeer S.E., Prins N.D., den Heijer T., Hofman A., Koudstaal P.J., and Breteler M.M. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 348 (2003) 1215-1222
17. Pearce K.A., Furberg C.D., and Rushing J. Does antihypertensive treatment of the elderly prevent cardiovascular events or prolong life?. A meta-analysis of hypertension treatment trials. Arch Fam Med 4 (1995) 943-949
18. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the elderly Program (SHEP). JAMA 265 (1991) 3255-3264
19. Perry Jr. H.M., Davis B.R., Price T.R., et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP). JAMA 284 (2000) 465-471
20. Hansson L., Lindholm L.H., Ekbom T., et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 354 (1999) 1751-1756
21. Ekbom T., Linjer E., Hedner T., et al. Cardiovascular events in elderly patients with isolated systolic hypertension: a subgroup analysis of treatment strategies in STOP-Hypertension-2. Blood Press 13 (2004) 137-141
22. Staessen J.A., Fagard R., Thijs L., et al., Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 350 (1997) 757-764
23. Forette F., Seux M.L., Staessen J.A., et al. Prevention of dementia in randomized double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 352 (1998) 1347-1351
24. Birns J., Morris R., Donaldson N., and Kalra L. The effects of blood pressure reduction on cognitive function: a review of effects based on pooled data from clinical trials. J Hypertens 24 (2006) 1907-1914
25. Li C., Engström G., Hedblad B., Berglund G., and Janzon L. Blood pressure control and risk of stroke: a population-based prospective cohort study. Stroke 36 (2005) 725-730
26. Beckett N.S., Connor M., Sadler J.D., Fletcher A.E., Bulpitt C.J., and HYVET Investigators. Orthostatic fall in blood pressure in the very elderly hyperensive: results from the Hypertension in the Very Elderly Trial (HYVET)-pilot. 1999. J Hum Hypertens 13 (1999) 839-840
27. Gueyffier F., Bulpitt C., Boissel J.P., et al., INDANA Group. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomized controlled trials. Lancet 353 (1999) 793-796
28. Turan T.N., Cotsonis G., Lynn M.J., Chaturvedi S., Chimowitz M., et al., Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) Trial Investigators. Relationship between blood pressure and stroke recurrence in patients with intracranial arterial stenosis. Circulation 115 (2007) 2969-2975
29. Roman G.C. Vascular dementia revisited: diagnosis, pathogenesis, treatment, and prevention. Med Clin North Am 86 (2002) 477-499
30. Dufouil C., Chalmers J., Coskun O., et al., PROGRESS MRI Substudy Investigators. Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy. Circulation 112 (2005) 1644-1650
31. Roman G.C. Brain hypoperfusion: a critical factor in vascular dementia. Neurol Res 6 (2004) 454-458
32. Ruitenberg A., Skoog I., Ott A., et al. Blood pressure and risk of dementia: results from the Rotterdam study and the Gothenburg H-70 Study. Dement Geriatr Cogn Disord 12 (2001) 33-39
33. Guo Z., Viitanen M., Fratiglioni L., and Winblad B. Low blood pressure and dementia in elderly people: the Kungsholmen project. BMJ 312 (1996) 805-808
34. Verghese J., Lipton R.B., Hall C.B., Kuslansky G., and Katz M.J. Low blood pressure and the risk of dementia in very old individuals. Neurology 61 (2003) 1667-1672
35. van Dijk E.J., Breteler M.M., Schmidt R., et al., CASCADE Consortium. The association between blood pressure, hypertension, and cerebral white matter lesions: cardiovascular determinants of dementia study. Hypertension 44 (2004) 625-630
36. Alves de Moraes S., Szklo M., Knopman D., and Sato R. The relationship between temporal changes in blood pressure and changes in cognitive function: Atherosclerosis Risk in Communities (ARIC) study. Prev Med 35 (2002) 258-263
37. in't Veld B.A., Ruitenberg A., Hofman A., Stricker B.H., and Breteler M.M. Antihypertensive drugs and incidence of dementia: the Rotterdam Study. Neurobiol Aging 22 (2001) 407-412
38. Qiu C., von Strauss E., Fastbom J., Winblad B., and Fratiglioni L. Low blood pressure and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Arch Neurol 60 (2003) 223-228
39. Anson O., and Paran E. Hypertension and cognitive functioning among the elderly: an overview. Am J Ther 12 (2005) 359-365
40. Goldstein L.B. Blood pressure management in patients with acute ischemic stroke. Hypertension 43 (2004) 137-141
41. Potter J., Robinson T., Ford G., et al., CHHIPS Trial Group. CHHIPS (Controlling Hypertension and Hypotension Immediately Post-Stroke) Pilot Trial: rationale and design. J Hypertens 23 (2005) 649-655
42. Ohkubo T., Hozawa A., Nagai K., et al. Prediction of stroke by ambulatory blood pressure monitoring versus screening blood pressure measurements in a general population: the Ohasama study. J Hypertens 18 (2000) 847-854
43. Verdecchia P., Reboldi G.P., Angeli F., et al. Short- and long-term incidence of stroke in white-coat hypertension. Hypertension 45 (2005) 203-208
44. Kario K., Ishikawa J., Pickering T.G., et al. Morning hypertension: the strongest independent risk factor for stroke in elderly hypertensive patients. Hypertens Res 29 (2006) 581-587
45. 1-receptor blockers. J Hum Hypertens 16 suppl 3 (2002) S64-S70
46. Fournier A., Messerli F.H., Achard J.M., and Fernandez L. Cerebroprotection mediated by angiotensin II: a hypothesis supported by recent randomized clinical trials. J Am Coll Cardiol 43 (2004) 1343-1347
47. Magy L., Vincent F., Faure S., et al. The renin-angiotensin systems: evolving pharmacological perspectives for cerebroprotection. Curr Pharm Des 11 (2005) 3275-3291
48. Ibrahim M.M. RAS inhibition in hypertension. J Hum Hypertens 20 (2006) 101-108
49. 2 receptor mRNA level after global ischemia in the rat brain. Neuropeptides 30 (1996) 596-601
50. Iadecola C., and Gorelick P.B. Hypertension, angiotensin, and stroke: beyond blood pressure. Stroke 35 (2004) 348-350
51. Dahlof B. Prospects for the prevention of stroke. J Hypertens Suppl 24 (2006) S3-S9
52. Nilsson P.M. Reducing the risk of stroke in elderly patients with hypertension: a critical review of the efficacy of antihypertensive drugs. Drugs Aging 22 (2005) 517-524
53. Thomas G.N., Chan P., and Tomlinson B. The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension. Drugs Aging 23 (2006) 131-155
54. Dahlöf B., Devereux R.B., Kjeldsen S.E., et al., LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 995-1003
55. Kjeldsen S.E., Dahlöf B., Devereux R.B., et al., LIFE Study Group. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 288 (2002) 1491-1498
56. Lithell H., Hansson L., Skoog I., et al., SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 21 (2003) 875-886
57. Papademetriou V., Farsang C., Elmfeldt D., et al., Study on Cognition and Prognosis in the Elderly Study Group. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol 44 (2004) 1175-1180
58. Schrader J., Lüders S., Kulschewski A., et al., MOSES Study Group. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 36 (2005) 1218-1226
59. Boutitie F., Oprisiu R., Achard J.M., et al. Does a change in angiotensin II formation caused by antihypertensive drugs affect the risk of stroke?. A meta-analysis of trials according to treatment with potentially different effects on angiotensin II. J Hypertens 25 (2007) 1543-1553
60. Diener H.C., Sacco R., Yusuf S., and Steering Committee of the PRoFESS Study Group. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovasc Dis 23 (2007) 368-380
61. Sleight P. The ONTARGET/TRANSCEND trial programme: baseline data. Acta Diabetol 42 suppl 1 (2005) S50-S56
62. JATOS Study Group. The Japanese Trial to Assess Optimal Systolic Blood Pressure in Elderly Hypertensive Patients (JATOS): protocol, patient characteristics, and blood pressure during the first 12 months. Hypertens Res 28 (2005) 513-520
63. Beckett N.S., Peters R., Fletcher A.E., et al., HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 358 (2008) 1887-1898
64. Peters R., Beckett N., Nunes M., et al. A substudy protocol of the hypertension in the Very Elderly Trial assessing cognitive decline and dementia incidence (HYVET-COG): an ongoing randomised, double-blind, placebo-controlled trial. Drugs Aging 23 (2006) 83-92